Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine - Pfizer

Next Previous
X
Search
Drug Profile

Azacitidine - Pfizer

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; BMS-986345; CC-486; Ladakamycin; NS-17; NSC-102816; Onureg; Oral-Aza; U-18496; VIDAZA; Vidaza

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb; Celgene Corporation; Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Kirby Institute for infection and immunity in society; Medical University of South Carolina; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Bologna; University of California, San Diego; University of Colorado at Denver; University of Kansas Medical Center; University of Leipzig; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase III T-cell lymphoma
  • Phase II Fallopian tube cancer; Graft-versus-host disease; HER2 negative breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Peripheral T-cell lymphoma; Peritoneal cancer
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Large granular lymphocytic leukaemia; Lymphoid leukaemia; Renal cancer; Solid tumours
  • No development reported Lymphoma; Multiple myeloma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy, Newly diagnosed) in USA (PO, Tablet)
  • 18 Jun 2024 Celgene completes phase III QUAZAR AML-001 trial in Acute myeloid leukaemia (First-line therapy) in Austria, Brazil, Canada, Czech Republic, Finland, Germany, Germany, Ireland, France, Italy, South Korea, Lithuania, Mexico, Poland, Portugal, Russia, Spain, Taiwan, Turkey, United Kingdom, United States (PO) (NCT01757535)
  • 31 May 2024 Efficacy and adverse event data from the phase II/III ASTREON trial in Myelodysplastic syndrome presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top